Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women

Clinical Drug Investigation

Volumn 32, Issue 10, 2012, Pages 697-705

  Geller, Elizabeth J ^a   Crane, Andrea K ^a   Wells, Ellen C ^a   Robinson, Barbara L ^a   Jannelli, Mary L ^a   Khandelwal, Christine M ^a   Connolly, AnnaMarie ^a   Parnell, Brent A ^a   Matthews, Catherine A ^a   Dumond, Julie B ^b   Busby Whitehead, Jan ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

Anticholinergic; Cognitive Function; Elderly.; Overactive Bladder

Indexed keywords

TROSPIUM CHLORIDE;

AGED; ARTICLE; BLADDER FUNCTION; CLINICAL ARTICLE; COGNITION; COHORT ANALYSIS; CONSTIPATION; CORRELATION ANALYSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; NAUSEA; OVERACTIVE BLADDER; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; URGE INCONTINENCE; XEROSTOMIA;

AGED; ATTENTION; CHOLINERGIC ANTAGONISTS; COGNITION; COHORT STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NORTROPANES; POSTMENOPAUSE; PROSPECTIVE STUDIES; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; VERBAL LEARNING;

EID: 84865506510     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11635010-000000000-00000     Document Type: Article

References (32)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327-36 (Pubitemid 44175300)
2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21 (1): 5-26
3. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005; 27 (2): 144-53 (Pubitemid 40462007)
4. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57 (6): 1044-50 (Pubitemid 32455563)
5. Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011; 59 (8): 1465-70
6. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int 2005; 96 Suppl. 1: 43-5 (Pubitemid 41224307)
7. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63 (3): 461-5
8. Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 2009; 15 (4 Suppl): S98-S107
9. Kay GG, Abou-Donia MB, Messer Jr WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53 (12): 2195-201 (Pubitemid 43001205)
10. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148 (5): 565-78 (Pubitemid 43993048)
11. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004; 5 (6): 423-6
12. Kaufer DI. Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response. CNS Spectr 2002; 7 (10): 742-50 (Pubitemid 36765066)
13. Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72 (2): 235-46
14. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56 (5): 862-70 (Pubitemid 351652413)
15. Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 2000; 6 (2): 314-8 (Pubitemid 30313168)
16. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug metabolism reviews 2009; 41 (2): 67-76
17. Pak RW, Petrou SP, Staskin DR. trospium chloride: a quaternary amine with unique pharmacologic properties. Current urology reports 2003; 4 (6): 436-40
18. Biastre K, Burnakis T. trospium chloride treatment of overactive bladder. Ann Pharmacother 2009; 43 (2): 283-95
19. STROBE statement-checklist of items that should be included in reports of observational studies (STROBE initiative). Int J Public Health 2008; 53 (1): 3-4
20. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 1991; 5: 125-42
21. Borson S, Scanlan JM, Chen P, et al. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003; 51 (10): 1451-4 (Pubitemid 37259876)
22. Katzman R, Brown T, Fuld P, et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983; 140: 734-9 (Pubitemid 13094139)
23. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 2005; 193 (1): 103-13 (Pubitemid 40991834)
24. Rogers RG, Coates KW, Kammerer-Doak D, et al. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor Dysfunct 2003; 14 (3): 164-8; discussion 8 (Pubitemid 41490366)
25. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56 (12): 2203-10
26. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011; 59 (8): 1477-83
27. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332 (7539): 455-9
28. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173 (2): 493-8
29. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64 (9): 1294-300
30. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004; 43 (9): 553-76 (Pubitemid 38951800)
31. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine oncedaily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57 (3): 414-21 (Pubitemid 32192963)
32. FDA. Sanctura XR® (trospium chloride) Extended Release: full prescribing information [online]. 2011. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/022103s004lbl.pdf, editor [Accessed 2012 Jul 1]